Jump to content

ASR-3001

Add links
From Wikipedia, the free encyclopedia

ASR-3001
Clinical data
Other namesASR3001; 5-MeO-iPALT; 5-MeO-ALiPT; 5-Methoxy-N-allyl-N-isopropyltryptamine
Routes of
administration		Oral[1]
Drug classSerotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Pharmacokinetic data
Onset of action≤15 minutes (as fast as 6–8 minutes)[1][2][3][4]
Duration of action1.5–2.5 hours[4][1]
Identifiers
  • N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-prop-2-enylpropan-2-amine
PubChem CID
Chemical and physical data
FormulaC17H24N2O
Molar mass272.392 g·mol−1
3D model (JSmol)
  • CC(C)N(CCC1=CNC2=C1C=C(C=C2)OC)CC=C
  • InChI=1S/C17H24N2O/c1-5-9-19(13(2)3)10-8-14-12-18-17-7-6-15(20-4)11-16(14)17/h5-7,11-13,18H,1,8-10H2,2-4H3
  • Key:MRWWDVFDOFUYKB-UHFFFAOYSA-N

ASR-3001, also known as 5-methoxy-N-allyl-N-isopropyltryptamine (5-MeO-iPALT), is a serotonin receptor agonist and serotonergic psychedelic of the tryptamine and 5-methoxytryptamine families which is under development for the treatment of psychiatric disorders.[5][1][2][3][6] It is a close analogue of related psychedelic tryptamines like 5-MeO-DALT, 5-MeO-DiPT, and 5-MeO-MiPT.[6]

The drug acts as a non-selective agonist of the serotonin receptors.[6] This includes of the serotonin 5-HT2A, 5-HT2B, 5-HT1A, 5-HT1B, and 5-HT6 receptors, whereas other serotonin receptors, such as the serotonin 5-HT2C receptor, were not described.[6] Its EC50Tooltip half-maximal effective concentration values were 9.85 nM at the serotonin 5-HT2A receptor, 46.8 nM at the serotonin 5-HT1B receptor, 87.4 nM at the serotonin 5-HT2B receptor, 420 nM at the serotonin 5-HT6 receptor, and 642 nM at the serotonin 5-HT1A receptor.[6] The drug was also a very weak serotonin reuptake inhibitor (IC50Tooltip half-maximal inhibitory concentration = 6,840 nM), but did not inhibit norepinephrine or dopamine reuptake.[6] It also showed little or no activity at various other sites.[6]

ASR-3001 is said to be orally active, fast- and short-acting, and to induce "an internal psychedelic cognitive state [or head space] with little or no sensory [or visual] involvement".[1][2][3][4] More specifically, it is said to have an absence of open-eye and closed-eye visuals.[4] These properties are expected to allow ASR-3001 to serve as a potential "entry point" for people reluctant to undergo a fully immersive psychedelic experience that includes visuals.[1][4] ASR-3001 is said to be internally psychedelic as opposed to entactogenic.[4] Its dose range is 8 to 14 mg (or perhaps up to 10 mg), its onset is within 15 minutes or as fast as 6 to 8 minutes, and its duration is short at about 1.5 to 2.5 hours (90–150 minutes).[1][2][3][4]

ASR-3001 is under development by the Nicholas V. Cozzi and Paul F. Daley and colleagues at the Alexander Shulgin Research Institute (ASRI).[5][1][4] It was first described by 2023 and was patented the same year.[1][6] As of early 2025, ASR-3001 is in the preclinical research stage of development.[5][7] It is the ASRI's most advanced developmental candidate.[4]

Other related analogues of ASR-3001 include ASR-3002 (2-Me-iPALT), ASR-3003 (iPALT), and ASR-3004 (PALT), among others.[6]

See also

[edit]

References

[edit]
  1. ^ a b c d e f g h i Goldstein L (10 July 2023). "Pioneering Psychedelics Scientist Alexander "Sasha" Shulgin's Legacy Lives On Via New Compounds And Research". Benzinga. Retrieved 19 April 2025.
  2. ^ a b c d Busby M (2 November 2023). "The Heirs to a Vault of Novel Psychedelics Take a Trip Into the Unknown". DoubleBlind Mag. Retrieved 19 April 2025.
  3. ^ a b c d Busby M (30 March 2025). "What Happens When You Inherit 500 Psychedelic Compounds?". DoubleBlind Mag. Retrieved 19 April 2025.
  4. ^ a b c d e f g h i Joe Moore (2 April 2024). "Shulgin Farm and the Future of Psychedelic Drug Development (Featuring: Paul F. Daley, Ph.D.)" (Podcast). Psychedelics Today. Event occurs at 16:12–20:45. Our most advanced compound right now is a tryptamine that's orally active, fast-onset, the latent period before you start to feel effects is as little as 6 to 8 minutes, relatively short-acting, 90 minutes to two and a half hours, and satisfyingly internally psychedelic as opposed to entactogenic. But interestingly no visual involvement. So there are no open-eyed, closed-eyed visuals, that aspect is just not present. [...] We think that there's probably a subset of patients who are, for whatever reason, reluctant to get into a full-immersion psychedelic experience, at least initially. So once they're more familiar with the territory, something like a psilocybin experience, something more intense and all-encompassing might be more easily tolerated if there are some training wheels in advance. So we think that compound has that role.
  5. ^ a b c "Delving into the Latest Updates on Tryptamine(ASRI) with Synapse". Synapse. 16 April 2025. Retrieved 19 April 2025.
  6. ^ a b c d e f g h i WO patent 2023034645A2, Paul Daley; Nicholas Cozzi & Wyeth Baillie Callaway, "Asymmetric allyl tryptamines", published 9 March 2023, assigned to Alexander Shulgin Research Institute 
  7. ^ Michael Haichin (2024). "Psychedelics Drug Development Tracker". Psychedelic Alpha. Retrieved 29 January 2025.
[edit]


Retrieved from "https://en.wikipedia.org/w/index.php?title=ASR-3001&oldid=1291109219"